Easton Pharmaceuticals Announces Update on Negotiations Towards Its
Medical Marijuana Initiatives
Easton Pharmaceuticals Announces Update on Negotiations Towards Its
Medical Marijuana Initiatives
TORONTO, ON--(Marketwired - Jan 16, 2014) - Easton
Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical
company that owns, designs, develops, and markets an array of
topically-delivered drugs and therapeutic healthcare products,
today announces an update to its previously announced Medical
Marijuana initiatives.
As previously disclosed in prior releases, Easton
Pharmaceuticals in its quest to enter into new lucrative business
segments and products, previously expressed its interest to enter
into the medical marijuana industry in both the U.S. and Canadian
Markets. Recent positive developments in the United States,
Canada and other countries such as Uruguay have added fuel and
optimism to the industry and what is possibly considered a vast and
extremely profitable business for participants in this industry.
Previous acquisitions made by Easton to enter into the Cancer drug
Industry as well as moving forward with the company's current
VIORRA initiatives in Mexico and in North America along with the
company's other line of products, has directed the company to
recently focus its priorities towards these two initiatives while
awaiting for positive catalysts in the medical marijuana industry
to materialize prior to making more concrete decisions towards
Medical Marijuana. Due to the recent positive legal changes and
attitudes towards Medical Marijuana and recreational Marijuana use
in general, Easton Pharmaceuticals is speeding up negotiations with
an Ontario, Canada based company towards forming a possible
investment / partnership towards their Medical Marijuana
initiatives which includes participating in their government
application for both a growers and distributorship license in
Canada and other possible international initiatives. This company
has obtained some private financing allowing it to recently file an
application for licenses and expressed confidence of a government
approval, however is not guaranteed. Additional updates and details
on these discussions including a possible agreement are expected to
be announced shortly. A Non Disclosure Agreement as well as
requests being made to Easton Pharmaceuticals to not make any name
disclosures at this point in time to avoid adversely affecting any
government applications submitted in November of 2013, are being
adhered to.
As of Jan. 01, the world's first pot shops opened for business
in Colorado, with more planned for Washington State. In Uruguay,
the first country to legalize marijuana, the government will
oversee the sale of Marijuana this spring, and in Canada, where
public support of pot has never been higher, new medical marijuana
laws will usher in a free market that produces high quality
cannabis to support a rapidly growing number of users. In the
United States there are 20 states that permit medical marijuana use
with New York State planning to do the same. Two of the 20 states
plan recreational use with other states also considering it. A
recent CNN survey had 55% of Americans support legalizing
Marijuana, up from 16% several years ago. According to a report by
the financial news firm See Change Strategy, the medical Marijuana
industry could conservatively reach nearly $9 billion nationwide in
the United States within five years, as more states in the United
States clear the way to likely legalize marijuana for medicinal
purposes. One of marijuana's greatest advantages as a medicine is
its remarkable safety. It is believed to have little effect on
major physiological functions. There is no known case of a lethal
overdose. On the basis of animal models, the ratio of lethal to
effective dose is estimated at 40,000 to 1. By comparison, the
ratio is between 3 and 50 to 1 for secobarbital, and between 4 and
10 to 1 for ethanol. It is believed, Marijuana is also far less
addictive and far less subject to abuse than many drugs now used as
muscle relaxants, hypnotics, and analgesics. The chief legitimate
concern is the effect of smoking on the lungs. Cannabis smoke
carries more tars and other particulate matter than tobacco smoke.
But the amount smoked is much less, especially in medical use, and
once marijuana is an openly recognized medicine, solutions may be
found such as vaporization, tinctures, extracts and oils. At
present, the greatest danger in medical use of marijuana is its
illegality, which imposes much anxiety and expense on suffering
people, forces them to bargain with illicit drug dealers, and
exposes them to the threat of criminal prosecution.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company
that owns, designs, develops, and markets topically-delivered Drugs
and therapeutic healthcare products, focused on Cancer and other
health issues related to male and female sexual dysfunction, wound
healing, pain, motion sickness, scar and stretch marks, cellulite,
varicose veins and other conditions. The company's gel formulation
is thought to be an innovative and unique transdermal delivery
system. Easton Pharmaceuticals product "VIORRA", is an
over-the-counter aid for the treatment to restore and improve
vaginal moisture and elasticity which is believed to have a
positive effect on women's sexual desire and arousal, FSAD (Female
Sexual Arousal Disorder) the world market for these female
conditions are in excess of $2 billion. VIORRA is a
topical, daily-use product classified by the FDA as containing
Generally Recognized as Safe ingredients.
For More Information Visit
http://www.eastonpharma.com
http://www.ashleybiomedical.com
Safe Harbor
This news release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(The "Act"). In particular, when used in the preceding of
discussion, the words "pleased," "plan," "confident that,"
"believe," "expect," "possible" or "intent to" and similar
conditional expressions are intended to identify forward-looking
statements within the meaning of the Act and are subject to the
safe harbor created by the Act. Such statements are subject to
certain risks and uncertainties and actual results could differ
materially from those expressed in any of the forward-looking
statements. Such risks and uncertainties include, but are not
limited to, market conditions, general acceptance of the company's
products and technologies, competitive factors, the ability to
successfully complete additional or adequate financing, government
approvals or changes to proposed laws and other risks and
uncertainties further stated in the company's financial reports and
filings.